The current randomized, double-blind, placebo-controlled clinical study will enroll approximately 48 patients at one clinical trial site in Beverly Hills, California.
Patients will be randomized to receive either GLYC-101 0.1% or GLYC-101 1% gel on one lower eyelid, and placebo on the other lower eyelid applied topically to the laser-ablated area immediately following the laser procedure and for four consecutive days thereafter.
The primary efficacy endpoint of the study is time to wound healing, and the secondary efficacy point is cosmetic outcomes, including scarring. The study will observe the effects of the topical agent over the course of one month following the initial treatment with the investigational compound and placebo.